MIR200C (microRNA 200c) by Mutlu, M et al.
  
 
 
   
Gene Section 
Review 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(4) 270 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
MIR200C (microRNA 200c) 
Merve Mutlu, Özge Saatçi, Umar Raza, Erol Eyüpoglu, Emre Yurdusev, Özgür Sahin 
Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, 06800, 
Ankara, Turkey (MM, ÖSaa, UR, EE, EY, ÖSah) 
 
Published in Atlas Database: July 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/MIR200CID51054ch12p13.html 
DOI: 10.4267/2042/56438 
This article is an update of : 
Jurmeister S, Uhlmann S, Sahin Ö. MIR200C (microRNA 200c). Atlas Genet Cytogenet Oncol Haematol 2012;16(2):92-99. 
 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Abstract 
MicroRNAs (miRNAs) are 20-22 nucleotide long 
small non-coding RNAs and have a function of 
regulation of gene postranscriptionally via targeting 
mainly the 3'UTRs of the genes. miR-200c is a 
member of miR-200 family with 4 other family 
members (miR-200a, miR-200b, miR-429 and miR-
141) located in chromosome 12 (12q13.31) together 
with miR-141. miRNAs can be classified as 
oncomiRs and tumor suppressors according to their 
target gene and which tissue they are expressed. 
miR-200c has been shown to be a tumor suppressor 
in various cancer types. miR-200c has been initially 
shown to regulate epithelial-mesenchymal 
transition (EMT) by downregulating ZEB1/2 and 
upregulating E-cadherin, known epithelial marker. 
Afterwards, it has been demonstrated that miR-
200c also have other important functions in 
proliferation, cell cycle control, apoptosis, anoikis, 
invasion, and metastasis of cancer and also in other 
diseases. Furthermore, miR-200c is a well-
established prognostic and diagnostic marker in 
different cancer types. 
Keywords 
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Identity 
Other names: hsa-mir-200c, MIRN200C, mir-200c 
 
HGNC (Hugo): MIR200C 
Location: 12p13.31 
Local order 
Based on MapViewer Genes on Sequence, genes 
flanking MIRN200C oriented from centromere to 
telomere on 12q13.31 are:  
- ATN1; atrophin 1, 12q13.31  
- U7; U7 small nuclear 1, 12q13.31  
- C12orf57; chromosome 12 open reading frame 57, 
12q13.31  
- PTPN6; protein tyrosine phosphatase, non-
receptor type 6, 12q13.31  
- MIRN200C; microRNA 200c, 12q13.31  
- MIRN141; microRNA 141, 12q13.31  
- snoU89; small nucleolar RNA U89, 12q31.1  
- PHB2; prohibitin 2, 12q31.1. 
DNA/RNA 
Description 
miR-200c belongs to the miR-200 family, which 
consists of 5 members with two different 
chromosomal locations: miR-200c and miR-141 are 
located on chromosome 12p13 and miR-200a, miR-
200b and miR-429 are located on 1p36.  
This family is frequently downregulated upon the 
progression of tumors and maps to fragile 
chromosomal regions.  
Members of this family are important regulators of 
epithelial-to-mesenchymal transition (EMT) and 
metastasis. 
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A. Stem-loop structure of hsa-mir-200c (precursor miRNA). B. The miR-200 family members. The human miR-200 family is 
located in two fragile chromosomal regions on 1p36.33 (200b, 200a and 429) and 12p13.31 (200c and 141), respectively. It 
consists of two clusters based on seed sequence similarity: miR-200bc/429 (red) and 200a/141 (blue), distinguished by a single 
nucleotide change (U to C) (source: Uhlmann et al., 2010, Oncogene). 
 
Transcription 
miRNAs are generally transcribed by RNA 
polymerase II. 
hsa-mir-200c (precursor miRNA) 
Accession: MI0000650 
Length: 68 bp 
Sequence: 5'-
CCCUCGUCUUACCCAGCAGUGUUUGGGUG
CGGUUGGGAGUCUCUAAUACUGCCGGGUA
AUGAUGGAGG-3' 
hsa-miR-200c* (-5p) (mature miRNA) 
Accession: MIMAT0004657 
Length: 23 
Sequence: 5'-
CGUCUUACCCAGCAGUGUUUGG-3' 
hsa-miR-200c-3p (mature miRNA) 
Accession: MIMAT0000617 
Length: 23 
Sequence: 5'-
UAAUACUGCCGGGUAAUGAUGGA-3' 
Pseudogene 
No reported pseudogenes. 
Protein 
Note 
microRNAs are not translated into proteins. 
Mutations 
Note 
1) rs12904G>A single nucleotide polymorphism in 
the 3'UTR sequence of EFNA1, a target of miR-
200c, results in susceptibility to gastric cancer (Li 
et al., 2014b).  
2) rs1045385A>C SNP in the 3'UTR sequence of 
AP-2a mRNA increases AP-2a expression and 
results in cisplatin resistance in HEC-1A cell line of 
endometrial cancer (Wu et al., 2011). 
Implicated in 
Cancer development 
See figure below. 
Bladder cancer 
Prognosis 
Loss of miR-200c expression was found to be 
associated with disease progression and poor 
outcome in 100 stage T1 bladder tumor patients 
(Wiklund et al., 2011a). Urinary miR-200 family 
levels are repressed in patients with bladder cancer 
(Wang et al., 2012). 
Oncogenesis 
Deep sequencing of nine bladder urothelial 
carcinomas (BUC) and matched normal urothelium 
revealed that the miR-200c/141 cluster is 
upregulated in bladder cancer (Han et al., 2011). 
Consistently, a study comparing miRNA expression 
patterns by microarray in 27 invasive and 30 
superficial bladder tumors with 11 normal urothelia 
found that miR-200c was upregulated in bladder 
tumors compared to normal urothelium; however, 
expression of miR-200c was reduced in invasive 
compared to non-invasive tumors due to promoter 
hypermethylation (Wiklund et al., 2011a). 
Furthermore, microarray miRNA analysis of 43 
primary tumors (10 colon, 10 bladder, 13 breast and 
10 lung cancers) and matched lymph node 
metastases revealed that miR-200c and other miR-
200 family members are downregulated in  
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miR-200c targets several genes regulating numerous processes involved in cancer development and progression. 
 
metastases compared to primary tumors (Baffa et 
al., 2009).  
Mechanistically, miR-200c has been implicated in 
the regulation of epithelial-to-mesenchymal 
transition (EMT) in bladder cancer cells. A 
comparison of nine bladder cancer cell lines 
revealed a correlation between high expression of 
miR-200c (and fellow miR-200 family member 
miR-200b) and epithelial phenotype (Adam et al., 
2009). The same study also reported that miR-200c 
expression reverses resistance to anti-EGFR 
therapy in bladder cancer cell lines through 
targeting ERRFI-1. 
However, contradictory to these results, in another 
study, it was found that the levels of miR-200c was 
upregulated in infiltrating BUC patients as 
compared with non-infiltrating BUC patients (Xie 
et al., 2012). These results were supported in a 
recent study, which again demonstrated that the 
levels of miR-200c were significantly higher in 
infiltrating carcinoma than in high grade bladder 
tumors (Lee et al., 2014). 
Breast cancer 
Prognosis 
Diagnosis. Circulating tumor cell (CTC)-positive 
metastatic breast cancer patients had significantly 
higher levels of miR-200c than CTC-negative 
metastatic breast cancer patients and miR-200c 
along with some other miRNAs were suggested to 
be potential predictive markers for CTC status of 
metastatic breast cancer patients (Madhavan et al., 
2012).  
miR-200c was found to be downregulated in breast 
cancer patients that are irresponsive to neoadjuvant 
chemotherapy than patients who respond (Chen et 
al., 2013c). 
Oncogenesis 
A double-negative feedback loop between ZEB 
family transcription factors and the miR-200 family 
was shown to regulate EMT in different cell 
systems, including breast cancer cells (Burk et al., 
2008). Moreover, expression of miR-200c was 
revealed to be activated by p53, resulting in 
induction of EMT in mammary epithelial cells upon 
loss of p53 (Chang et al., 2011). Loss of p53 was 
positively correlated with expression of ZEB1 and 
negatively correlated with expression of miR-200c 
and E-Cadherin in 106 breast tumor specimens.  
miRNA microarray analysis of 43 primary tumors 
(10 colon, 10 bladder, 13 breast and 10 lung 
cancers) and matched lymph node metastases 
revealed that miR-200c and other miR-200 family 
members are downregulated in metastases 
compared to primary tumors (Baffa et al., 2009). 
Moreover, miR-200c and other miR-200 family 
members were shown to be underexpressed in the 
aggressive claudin-low subtype of breast cancer, 
which displays an EMT-like gene expression 
signature (Herschkowitz et al., 2011). In contrast, 
luminal breast cancers, which have a more 
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epithelial-like phenotype and a better clinical 
prognosis, express high levels of miR-200c 
(Bockmeyer et al., 2011). Besides ZEB family, 
miR-200c can modify metastasis by targeting 
HMGB1, ZNF217 and a truncated form of VEGFR-
1 (Chang et al., 2014a; Bai et al., 2014b; Mezquita 
et al., 2014). miR-200c was also found to be an 
inhibitor of tumor progression and therapy 
resistance by targeting KRAS and ZNF217 (Bai et 
al., 2014b; Kopp et al., 2014). 
Re-expression of the miR-200 family in aggressive 
breast cancer cells was shown to inhibit 
experimental lung metastasis (Ahmad et al., 2011) 
and decreased expression of it is associated with 
lymph node metastases in triple negative breast 
cancer (Berber et al., 2014). In contrast, another 
study reported that miR-200c is upregulated in 
breast cancer patients with lymph node metastasis 
(Wang et al., 2013). It was also shown to promote 
colonization of breast cancer cells (Dykxhoorn et 
al., 2009). The level of miR-200c was also found to 
be high in patients with various cancers including 
breast cancer that develop poly-metastases and it 
was reasoned that miR-200c is aiding colonization 
in the late stages of metastasis by reverting EMT 
(Lussier et al., 2011). In in vitro assays, miR-200c 
suppresses migration and invasion of breast cancer 
cells through various mechanisms, including 
targeting of ZEB1/ZEB2, PLCG1, moesin and 
fibronectin (Korpal et al., 2008; Uhlmann et al., 
2010; Howe et al., 2011; Gerhauser, 2013).  
miR-200c also targets stem cell factors such as 
BMI1, and downregulation of miR-200c was shown 
to be characteristic of breast cancer stem cells 
(Shimono et al., 2009) and DNA methylation was 
found to be the cause of the repression in breast 
cancer stem cell like populations (Lim et al., 2013). 
A natural compound, resveratrol, is increasing the 
activity of Ago2 and as a result inhibiting breast 
cancer stem cell-like characteristics by increasing 
the activity of tumor suppressor miRNAs including 
miR-200c (Hagiwara et al., 2012).  
Furthermore, miRNA microarray analysis revealed 
that miR-200c is downregulated in breast cancer 
cells with acquired resistance to cisplatin (Pogribny 
et al., 2010). It was also found to be downregulated 
in doxorubicin resistant MCF-7 and BT474 breast 
cancer cells (Chen et al., 2013c; Kopp et al., 2012). 
It was also associated with trastuzumab resistance, 
which was found to be reverse by upregulation of 
miR-200c through the blockage of TGF-B signaling 
(Bai et al., 2014b).  
miR-200c is also associated with increase in 
radiosensitivity in breast cancer cells by inhibiting 
cell proliferation, and by increasing apoptosis and 
DNA double-strand breaks. TBK1 was found to be 
a direct target of miR-200c and its downregulation 
by miR-200c is partially responsible for increased 
apoptosis (Lin et al., 2013). 
CAFs and microenvironment 
Oncogenesis 
Eleven dysregulated miRNAs including miR-200c 
were identified in cancer-associated fibroblasts 
(CAFs) cultured from six resected breast tumor 
tissues that had not previously received 
radiotherapy or chemotherapy treatment. MiR-200c 
was found to be up-regulated in CAFs compared to 
normal fibroblasts (NFs) (Zhao et al., 2012). miR-
200c targets Flt1/VEGFR1 gene which play an 
important role in enhancement of cell invasion in 
CAFs isolated from murine lung adenocarcinomas 
(Roybal et al., 2011). 
Colorectal cancer 
Prognosis 
Kaplan-Meier survival analysis of 24 colorectal 
cancer patients suggested that high expression of 
miR-200c was associated with decreased overall 
survival (Xi et al., 2006). miR-200c levels in 
plasma and serum can serve as a potential 
noninvasive biomarker for CRC 
prognosis/screening and predicting metastasis 
(Zhang et al., 2013; Toiyama et al., 2014). 
Fluoropyrimidines treated two separate groups of 
individuals showed high levels of miR-200c, along 
with other members of miR-200 family, and found 
associated with longer overall and disease-free 
survival (Diaz et al., 2014). 
Oncogenesis 
Analysis of miR-200c expression in 24 colorectal 
cancer (CRC) biopsies and matched normal 
samples by qRT-PCR revealed that miR-200c is 
overexpressed in CRC tumors compared to normal 
tissue (Xi et al., 2006). Furthermore, microarray 
miRNA analysis of 43 primary tumors (10 colon, 
10 bladder, 13 breast and 10 lung cancers) and 
matched lymph node metastases revealed that miR-
200c and other miR-200 family members are 
downregulated in metastases compared to primary 
tumors (Baffa et al., 2009). miR-200c was also 
among miRNAs found upregulated in CRC tissue 
as compared to normal colonic mucosa shown in a 
microarray analysis followed by RT-PCR (Tsunoda 
et al., 2011). K-Ras driven expression of miR-200c 
and other miRNAs in a 3D culture specific manner 
suggested a role for miR-200c in regulating 
colorectal tumor development in vivo (Tsunoda et 
al., 2011; Ota et al., 2012). In an independent study, 
miR-200c was found to be associated with the 
development of CRC (Chen et al., 2012). By 
directly tageting ZEB1, miR-200c inhibited 
metastasis in CRC cells SW480/620 (Chen et al., 
2012). Epigenetically regulated low expression of 
miR-200c contributes to EMT and metastatic 
potential of CRC, and transfecting CRC cells lines 
with miR-200c lead to increased proliferation but 
reduced invasion and migration (Hur et al., 2013). 
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miR-200c regulates Sox2 expression in a negative 
feedback loop in CRC and this regulation is 
associated with stemness, growth and metastatic 
potential of CRC (Lu et al., 2014). On the contrary, 
miR-200c has also been shown to work as 
oncogene in CRC where it takes part in inhibiting 
apoptosis and its silencing leads towards 
upregulation of Pten and p53 tumor suppressor 
genes (Chen et al., 2014b). 
Endometrial cancer 
Disease 
Endometrial carcinoma; endometrial 
carcinosarcoma. 
Prognosis 
miR-200c was shown to be a prognostic marker of 
overall survival. High levels of miR-200c were 
associated with lower chance of survival in patients 
with endometrioid endometrial cancer (Torres et al., 
2013). 
Oncogenesis 
miRNA microarray analysis of four endometrial 
endometrioid carcinomas and four normal 
endometrial tissue samples showed that miR-200c 
and other miR-200 family members were 
overexpressed in cancerous compared to normal 
tissue (Lee et al., 2011). These results were 
supported by other studies which showed that miR-
200c expression is significantly upregulated in 
endometrial tumors compared to normal tissues 
(Karaayvaz et al., 2012) as well as to complex 
atypical hyperplasia (CAH) and simple hyperplasia 
(SH) cases (Lee et al., 2012). Inhibition of miR-
200c decreased the growth of endometrial 
carcinoma cells (Lee et al., 2011). It was shown that 
it inhibits the expression of BRD7, which was 
reported as a potential tumor suppressor gene that 
prevents B-catenin from entering into nuclues. 
Inhibition of BRD7 by miR-200c results in 
increased expression of B-catenin transcriptional 
target genes, cyclin D1 and c-myc (Park et al., 
2012). Inhibition of miR-200c decreased the growth 
of endometrial carcinoma cells (Lee et al., 2011). In 
contrast, an analysis of miR-200c expression levels 
in five endometrial cancer and normal endometrial 
cell lines suggested that miR-200c is lower in cell 
lines derived from aggressive cancer compared to 
those derived from less aggressive cancer or normal 
endometrial epithelium (Cochrane et al., 2009). 
Restoration of miR-200c expression in aggressive 
endometrial cancer cells reduced their migration 
and invasion and increased their sensitivity to 
microtubule-targeting chemotherapeutic agents, at 
least in part through targeting TUBB3 (Cochrane et 
al., 2009; Cochrane et al., 2010; Howe et al., 2011). 
In a panel of 23 endometrial carcinosarcomas, 
which are composed of mixed populations of 
epithelial-like and mesenchymal-like cells, miR-
200c and other miR-200 family members were 
found to be downregulated in the mesenchymal 
components of the tumors compared to the 
epithelial components (Castilla et al., 2011) and it 
was found to be methylated during EMT in both in 
vitro and in vivo models (Díaz-Martín et al., 2014). 
These results are consistent with the established 
role of the miR-200 family in suppression of 
epithelial- mesenchymal transition. 
Esophageal cancer 
Prognosis 
In a panel of 98 esophageal cancer patients treated 
with preoperative chemotherapy and surgery, 
expression of miR-200c was associated with 
shortened overall survival and poor response to 
chemotherapy, potentially through upregulation of 
the Akt signaling pathway (Hamano et al., 2011). In 
another study higher miR-200c expression in serum 
collected from 64 esophageal cancer patients who 
have received neoadjuvant chemotherapy has 
shown to be associated with poor response to 
chemotherapy and shortened progression free 
survival (Tanaka et al., 2013). 
Oncogenesis 
qRT-PCR analysis of miR-200 expression levels in 
17 patients with Barrett's esophagus and 20 patients 
with esophageal adenocarcinoma indicated that 
miR-200c is downregulated during cancer 
progression from normal epithelium through 
Barrett's esophagus to esophageal adenocarcinoma 
(Smith et al., 2011). In contrast, another study on 
98 esophageal cancer patients treated with 
preoperative chemotherapy and surgery found that 
miR-200c was expressed at higher levels in the 
tumor than in normal tissue (Hamano et al., 2011). 
Gastric cancer 
Prognosis 
Significantly higher expression level of miR-200c 
in blood has been observed in gastric cancer 
patients as compared to controls and also found as 
good predictor of overall and progression free 
survival in gastric cancer patients (Valladares-
Ayerbes et al., 2012). miR-200c, mir-200b and 
miR-125 were found to be targeting most of the 
genes driving mesenchymal subtype of gastric 
cancer; a subtype which is associated with poor 
overall survival in gastric cancer. Functional 
analysis showed that miR-200b suppresses ZEB1, 
augments E-cadherin and inhibit cell migration and 
tumor growth in a mouse model (Song et al., 2014). 
Oncogenesis 
Three miRNAs from miR-200 family (miR-200a, -
200b, -200c) found downregulated in gastric 
adenocarcinoma and miR-200a, when upregulated, 
suppressed EMT and tumor growth by modulating 
Wnt/β-catenin signaling pathway through targeting 
MIR200C (microRNA 200c) Mutlu M, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(4) 275 
ZEB1 and ZEB2 (Cong et al., 2013). Co-delivering 
miR-200c with docetaxel by nanoparticles 
significantly enhanced cytotoxicity of docetaxel and 
suppressed tumor growth in vivo possibly by 
decreasing TUBB3 levels and by reversing EMT 
(Liu et al., 2013). miR-200b and miR-200c, when 
overexpressed in gastric cancer cells, reduced DNA 
methylation by targeting DNMT3A, DNMT3B and 
SP1, and also reduced tumor growth and migration 
capacity by re-expressing of p16, RASS1A1, and 
E-cadherin (Tang et al., 2013). Overexpressing 
miR-200c in gastric cancer tissues and cells 
(SGC7901 and SGC7901/DDP) led to enhancing 
cisplatin sensitivity in these cells possibly by 
targeting RhoE (Chang et al., 2014b). miR-141, 
another member of miR-200 family, also found 
suppressing proliferation, colony formation, 
migration and invasion capabilities of gastric cancer 
cells partially by targeting HDGF (Chen et al., 
2014a). A study conducted on miRNA binding site 
SNPs located in the 3'UTRs of genes involved in 
gastric cancer susceptibility revealed that ephrin-A1 
(EFNA1) gene is significantly associated with risk 
of gastric cancer as miR-200c binding site SNP 
(rs12904 G>A) in the 3'UTR of EFNA1 can 
significantly modulate EFNA1 expression (Li et al., 
2014b). 
Germ cell tumors 
Disease 
Germinoma; yolk sac tumors. 
Prognosis 
Diagnosis. Microarray analysis of 25 germ cell 
tumors and subsequent validation by qRT-PCR in 
10 independent samples identified miR-200c 
overexpression in yolk sac tumors compared to 
germinoma (Murray et al., 2010). 
Head and neck cancer 
Disease 
Squamous cell carcinoma; spindle cell carcinoma. 
Oncogenesis 
miR-200c was significantly downregulated in a 
panel of 30 spindle cell carcinomas (which display 
a mesenchymal-like phenotype) compared to 
normal mucosa as determined by qRT-PCR (Zidar 
et al., 2011). In contrast, expression levels of miR-
200c in 30 squamous cell carcinomas were 
comparable to normal tissue. A xenotransplantation 
study has shown that miR-200c directly targets 
BMI1 and overexpression of miR-200c or BMI1 
knockdown inhibited lung metastasis and prolonged 
the survival of mice suggesting therapeutic 
potential miR-200c in head and neck squamous cell 
carcinoma (Lo et al., 2011). HGF-driven 
downregulation of miR-200c leads to enhanced 
ZEB1/E-cadherin mediated epithelial to 
mesenchymal transition in head and neck squamous 
cell carcinoma (Susuki et al., 2011). miR-200c, 
along with other miRNAs, play important roles e.g., 
regulation of stemness and epithelial mesencymal 
transition in head and neck tumor cells (Tu et al., 
2013). Targeting HPV 16 E6-p300 interaction with 
a CH1-domain inhibitor resulted in enhanced 
functional reactivation of p53 tumor suppressor as a 
result of upregulation of miR-200c and miR-34a 
expression levels (Xie et al., 2014). In head and 
neck squamous cell carcinoma, promoter 
hypermethylation of miR-200c targets (Zeb1/Zeb2) 
has been reported to somehow mask the effects 
associated with miR-200 family regulation of EMT 
and migration (Tamagawa et al., 2014). 
Huntington' disease 
Cytogenetics 
A significant alteration of miR-200 family 
members, miR-200a, and miR-200c has been 
observed in the cerebral cortex and the striatum, at 
the early stage of disease progression in a mouse 
model of Huntington's disease. Elevated levels of 
miR-200c results in downregulation of some target 
genes, which have been suggested to play important 
roles in synaptic function, axonal trafficking, 
neurotransmitter release, neurogenesis, and 
neuronal survival (Jin et al., 2012). 
Leiomyomas 
Oncogenesis 
It was found that TIMP2, FBLN5, and VEGFA as 
direct targets of miR-200c in leiomyomas and the 
expression of miR-200c was significantly lower in 
leiomymas compared to matched myometrium 
(Chuang et al., 2012). 
Liver cancer 
Prognosis 
Diagnosis. miR-200c has been suggested as a 
biomarker to distinguish hepatocellular carcinoma 
from liver metastases (Barshack et al., 2010).  
miR-429, a member of miR-200 family, was shown 
to be a prognostic marker in a hepatocellular 
carcinoma (HCC) tissue microarray study as it was 
upregulated and shown to promote liver tumor 
initiating cell properties by targeting Rb binding 
protein 4 (Li et al., 2014a). 
Oncogenesis 
miRNA microarray analysis of 92 primary 
hepatocellular carcinomas and 9 HCC cell lines 
identified miR-200c as a microRNA that is 
upregulated by p53 (Kim et al., 2011). Increased 
expression of miR-200c results in downregulation 
of transcriptional repressors ZEB1 and ZEB2, 
suggesting a role for p53-mediated regulation of 
miR-200c in suppression of EMT. miR-200c was 
reported to be underexpressed in benign liver 
tumors compared to HCC (Ladeiro et al., 2008); 
miR-200c levels were determined by qRT-PCR in 
MIR200C (microRNA 200c) Mutlu M, et al. 
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two sets of tumors (first set: 18 benign tumors, 28 
hepatocellular carcinomas; second set: 12 benign 
tumors, 22 hepatocellular carcinomas). miR-200c, 
along with other miRNAs, was found to be 
downregulated in both HCC and intrahepatic 
cholangiocarcinoma (ICC) (Karakatsanis et al., 
2013). Targeting liver cancer cells with miR-200b, 
member of miR-200 family, not alone but 
simultaneously with DNA methyl transferase 
inhibitor reduced the metastatic potential of these 
cells irrespective of E-cadherin levels (Ding et al., 
2012). Transcriptome profiling of 23 ICC and 
combined HCC tumor specimens using microarrays 
have revealed miR-200c/EMT as common 
signaling pathway activated in ICC stem cells. 
Furthermore, NCAM1, known hepatic stem cell 
marker, was found to be a direct target of miR-200c 
(Oishi et al., 2012). While analyzing the expression 
of a member of miR-200 family, miR-429, in 138 
pathology diagnosed HCC patients, this miRNA 
was found upregulated in tumor tissues and 
contributing to cell proliferation and inhibiting 
apoptosis (Huang et al., 2013). Simultaneous 
silencing of miR-141 and miR-200c has been 
reported to be responsible for developing HCC with 
bile duct tumor thrombosis by activation of ZEB-1 
mediated EMT in a study conducted on patients 
having HCC with or without bile duct tumor 
thrombus (Yeh et al., 2014). 
Lung cancer 
Prognosis 
qRT-PCR analysis of miR-200c expression levels 
in 70 non-small cell lung cancer (NSCLC) patients 
revealed that high expression of miR-200c was 
associated with reduced overall survival (Liu et al., 
2011). Another study investigated serum 
microRNAs as cancer biomarkers showed that 
miR200c is associated with NSCLC, suggesting a 
potential usage for diagnosis (Liu et al., 2012b). 
Re-expression of miR-200 family miRNAs has 
been found to target and downregulate the 
previously identified prognostic biomarkers in 
metastatic NSCLC suggesting the importance of 
these miRNAs in regulating metastatic potential of 
lung cancer (Pacurari et al., 2013). 
Oncogenesis 
Treatment of immortalized human bronchial 
epithelial cells with tobacco carcinogens was shown 
to induce an EMT-like phenotype and stem-cell like 
properties (Tellez et al., 2011). Quantification of 
miRNA levels by qRT-PCR in combination with 
bisulfite sequencing and chromatin 
immunoprecipitation revealed that these changes 
are accompanied by epigenetic silencing of miR-
200c and other EMT-regulating microRNAs, 
suggesting that loss of miR-200c contributes to 
transformation of lung epithelial cells. In contrast, 
miRNA microarray analysis of six NSCLCs and 
matched adjacent normal tissue revealed that miR-
200c is upregulated in NSCLC compared to healthy 
tissue (Liu et al., 2011). This finding was further 
validated in 70 lung carcinomas and matched 
normal tissue by qRT-PCR.  
Several studies have reported that miR-200c can 
repress invasion and metastasis of lung cancer cells. 
Firstly, low expression of miR-200c and other miR-
200 family members was associated with increased 
metastatic potential in a syngeneic mouse model of 
lung adenocarcinoma, and re-expression of miR-
200 family members in these cell lines prevented 
EMT and metastasis (Gibbons et al., 2009). 
Secondly, miR-200c was shown to be 
downregulated by promoter hypermethylation in 
invasive NSCLC cell lines, and re-expression of 
miR-200c reduced the invasive potential of these 
cell lines (Ceppi et al., 2010). Furthermore, 
microarray miRNA analysis of 43 primary tumors 
(10 colon, 10 bladder, 13 breast and 10 lung 
cancers) and matched lymph node metastases 
revealed that miR-200c and other miR-200 family 
members are downregulated in metastases 
compared to primary tumors (Baffa et al., 2009). 
Finally, low expression of miR-200c in 69 primary 
lung tumors was correlated with lymph node 
metastases (Ceppi et al., 2010).  
Mechanistically, the Notch ligand Jagged2 was 
shown to suppress expression of miR-200 family 
members, resulting in induction of EMT and 
increased metastatic potential (Yang et al., 2011). 
Moreover, miR-200c and fellow miR-200 family 
member miR-200b target VEGFR, which also 
contributes to invasion and metastasis (Roybal et 
al., 2011). 
It was demonstrated that miR-200c which is 
normally downregulated in lung cancer tissue, is 
upregulated by transfection in H460 cells resulted 
in higher levels of apoptotic cells in comparison 
with untransfected ones (Bai et al., 2014a). In 
addition, miR-200c enhanced the antitumor effect 
of reservatol (RESV).  
Drug sensitivity can be restored in EMT driven 
erlotinib (EGFR inhibitor) resistant NSCLC by 
using a single agent, silibinin, which fully reverses 
the high miR-21/low miR-200c signature and 
represses mesenchymal markers SNAIL, ZEB and 
N-Cadherin (Cufí et al., 2013). Moreover, VEGF 
family is an important regulator of angiogenesis 
and VEGFR2 has been identified as direct target of 
miR-200c. Ectopic miR-200c expression radio-
sensitized the A549 cells by VEGF-VEGFR2 
pathway leading to inhibition of its downstream 
pro-survival signaling and angiogenesis (Shi et al., 
2013). Finally, acquired resistance to EGFR 
inhibitors in lung cancer cells is found to be 
associated with EMT (characterized by 
downregulation of miR-200c) and/or stem like 
properties (increased ALDH1A1 levels, increase of 
MIR200C (microRNA 200c) Mutlu M, et al. 
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side population and self renewal capability) (Shien 
et al., 2013). 
Lymphoma 
Prognosis 
High expression levels of miR-200c was found to 
be associated with decreased overall survival and 
time from initial diagnosis to the first relapse in 
diffuse large B-cell lymphoma (DLBCL) (Berglund 
et al., 2013). 
Oncogenesis 
miR-200c was found directly targeting polycomb 
protein BMI1 In radiation induced thymic 
lymphoma (RITL) model of BALB/c mice and 
adenovirus mediated overexpression of miR-200c 
reduced tumorigenesis in vivo suggesting it as a 
novel therapeutic method to treat RITL (Cui et al., 
2014). Genome-wide expression profiling of nine 
H. pylori-positive and nine H. pylori-negative 
gastric diffuse large B-cell lymphomas and further 
confirmation in 30 samples for each has revealed 
that miR-200c inhibits ZEB1 in H. pylori-positive 
gastric diffuse large B-cell lymphoma which, in 
turn, upregulates BCL6 and results in less 
aggressive behavior of H. pylori-positive gastric 
diffuse large B-cell lymphomas (Huang et al., 
2014). 
Malignant pleural mesothelioma 
Prognosis 
Diagnosis. miR-200c has been proposed as a 
biomarker to distinguish malignant pleural 
mesothelioma from lung adenocarcinoma and lung 
metastases of other carcinomas. miRNA microarray 
expression profiling of 10 lung adenocarcinomas 
and 15 mesotheliomas revealed that miR-200c is 
reduced in mesothelioma (Gee et al., 2010). This 
result was further confirmed by qRT-PCR in a set 
of 100 mesotheliomas and 32 lung 
adenocarcinomas. Similarly, microRNA microarray 
analysis of 7 malignant pleural mesotheliomas and 
97 carcinomas of various origins also identified 
miR-200c as underexpressed in mesotheliomas 
compared to the carcinoma samples, and 
differential expression levels of miR-200c and two 
other microRNAs could successfully be used to 
distinguish between malignant pleural 
mesothelioma and other types of cancer (Benjamin 
et al., 2010). 
Melanoma 
Oncogenesis 
Analysis of miR-200c expression levels in a panel 
of 10 melanoma cell lines by qRT-PCR showed that 
miR-200c is overexpressed in many of these cell 
lines compared to normal melanocytes (Elson-
Schwab et al., 2010). On the contrary, 
overexpression of miR-200c in melanoma cells 
significantly decreased proliferation, migratory 
capacity and drug resistance by targeting BMI-1, 
ABCG2, ABCG5, and MDR1 and enhancing E-
cadherin levels. Overexpression of miR-200c also 
inhibited melanoma xenograft growth and 
metastasis in vivo (Liu et al., 2012a). Decreased 
levels of miR-200a, miR-200c, and miR-203 
correlated with increasing tumor thickness in a 
series of 23 frozen primary melanomas. A 
functional validation study using an anti-miR200 
strategy demonstrated that loss of miR-200 
expression in melanoma cell lines reduced E-
cadherin expression (van Kempen et al., 2012). 
Overexpressing miR-200c in mouse melanoma 
B16F10 CD44+CD133+ CSCs led to the reduced 
cell proliferation, colony formation, cell migration 
and invasion potential in vitro as well as 
tumorigenicity in vivo but not in B16F10 cells and 
B16F10 non-CD44+ CD133+ CSCs (Dou et al., 
2013). 
Oral squamous carcinoma 
Prognosis 
Significant expression alteration of miR-200 family 
including miR-200c was shown in oral squamous 
carcinoma patients compared to healthy controls 
tested from saliva. This demonstrates a potential 
biomarker property of miR-200c that can be used in 
clinical application with oral rinse (Wiklund et al., 
2011b). 
Ovarian cancer 
Prognosis 
High expression of miR-200c was found correlated 
with decreased progression-free and overall 
survival in a panel of 20 serous ovarian cancer 
patients (Nam et al., 2008). In contrast, a study 
investigating microRNA expression profiles in a 
total of 144 patients with epithelial ovarian cancer 
found that low expression of miR-200c was 
associated with increased progression-free and 
overall survival (Marchini et al., 2011).  
Similarly, high expression of miR-200c was 
correlated with response to chemotherapy and 
decreased risk of disease recurrence in a panel of 57 
patients with serous ovarian carcinoma (Leskela et 
al., 2010). In a study for identification of 
differentially expressed miRNAs in high-grade 
serous ovarian carcinoma (HGSC), clear cell 
ovarian carcinoma (CCC) and ovarian surface 
epithelium (OSE), high miR-200c-3p expression 
has been associated with poor progression-free (p = 
0.031) and overall (p = 0.026) survival in HGSC 
patients (Kim et al., 2014).  
Diagnosis. MiR-200c along with other miR-200 
family miRNAs (miR-141, miR-200a, miR-200b) 
has been found preferentially upregulated in 
epithelial ovarian cancer suggesting its role as a 
potential biomarker for this cancer type (Chen et 
al., 2013d). 
MIR200C (microRNA 200c) Mutlu M, et al. 
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Oncogenesis 
miR-200c was found to be overexpressed in a panel 
of 20 serous ovarian carcinomas compared to 8 
normal ovarian tissues by miRNA microarray 
analysis (Nam et al., 2008). Similarly, increased 
expression of miR-200c compared to normal ovary 
(n=15) was reported for serous, endometrioid and 
clear cell ovarian carcinoma in a series of 69 cancer 
specimens.  
Expression of miR-200c was correlated with E-
Cadherin levels in 36 primary ovarian carcinomas 
(Park et al., 2008). The regulatory effect of miR-
200c on EMT has been shown to be mediated 
through targeting of ZEB1 and ZEB2, which 
transcriptionally repress E-Cadherin (Gregory et al., 
2008; Korpal et al., 2008; Park et al., 2008). In this 
same line of comparative study, miRNA microarray 
and qPCR analysis, it has been shown elevated 
expression level of miR-200c on ovarian carcinoma 
effusions (Vaksman et al., 2011).  
Re-expression of miR-200c in aggressive ovarian 
cancer cell lines was shown to reduce their 
migratory capacity; however, this effect appears to 
be independent of E-Cadherin expression 
(Cochrane et al., 2010). Furthermore, forced 
expression of miR-200c has been reported to 
sensitize ovarian cancer cells to paclitaxel treatment 
due to downregulation of miR-200c target gene 
TUBB3 (Cochrane et al., 2009; Cochrane et al., 
2010). Reduction in endogenous PTEN levels and 
upregulation of phopho-Akt levels were reported in 
miR-200c transfected ovarian cancer stem cells 
(OCSCs) (Luo et al., 2013). miR-200c was also 
shown to be downregulated in a subpopulation of 
the ovarian cancer cell line OVCAR3 expressing 
the cancer stem cell marker CD133 (Guo et al., 
2011). In CD117+ CD44+ OCSCs, miR-200c 
expression has been reduced. Overexpression of 
miR-200c in these OCSCs upregulated E-cadherin 
expression, downregulated ZEB-1 and Vimentin 
expression in vitro. Also miR-200c upregulation 
showed inhibitory effect in CD117+ CD44+ 
OCSCs in xenograft growth and lung metastasis in 
nude mice (Chen et al., 2013b). 
Pancreatic cancer 
Prognosis 
In a panel of 99 pancreatic cancer patients, high 
expression of miR-200c was associated with 
increased overall survival (Yu et al., 2010). 
Oncogenesis 
Downregulation of miR-200c and other miR-200 
family members has been observed in gemcitabine-
resistant pancreatic cancer cell lines (Li et al., 2009; 
Ali et al., 2010). miR-200c has also been suggested 
to have a stemness-inhibiting function in pancreatic 
cancer cells through targeting of stem cell factors 
such as Bmi1 (Wellner et al., 2009).  
A double-negative feedback loop between ZEB 
family transcription factors and the miR-200 family 
was shown to regulate EMT in different cell 
systems, including pancreatic cancer cells (Burk et 
al., 2008). Consistently, high expression of miR-
200c was shown to be associated with decreased 
invasive behavior in a panel of six pancreatic 
cancer cell lines, and miR-200c expression was 
correlated with E-Cadherin levels in pancreatic 
cancer specimens and cell lines (Yu et al., 2010). 
Overexpression of miR-200c in pancreatic cancer 
cell lines resulted in upregulation of E-Cadherin 
expression and reduced invasion but stimulated 
proliferation. 
miRNA expression profiling of various stages in a 
mouse model of multistep tumorigenesis of the 
pancreas revealed that miR-200c is downregulated 
in metastases and metastasis-like tumors (Olson et 
al., 2009). Moreover, miR-200c also targets 
components of the Notch pathway, which is 
aberrantly activated in pancreatic cancer (Brabletz 
et al., 2011). Undifferentiated, aggressive 
pancreatic adenocarcinomas were shown to have 
higher expression of ZEB1 and Notch pathway 
components and lower expression of miR-200c 
compared to differentiated tumors. 
In contrast to the studies described above, which 
suggest a metastasis-suppressing function for miR-
200c in pancreatic cancer, a comparison of 16 
pancreatic ductal adenocarcinoma cell lines found 
that miR-200c expression was upregulated in the 
highly metastatic cell lines (Mees et al., 2010). 
Interaction of MUC1 and ZEB1 at the promoter of 
miR-200c/141, results in transcriptional repression 
of these miRNAs leading to enhanced progression 
of pancreatic cancer (Mohr et al., 2013). In addition 
to regulation of proteins that modulate EMT in 
pancreatic adenocarcinoma, miR-200c has also 
been found to target cell surface mucins (MUC4 
and MUC16), which play essential role in 
progression and metastasis in pancreatic 
adenocarcinoma (Radhakrishnan et al., 2013). In 
another study it was shown how metformin 
provokes the death of cancer stem cells in human 
pancreatic cancer cells (Bao et al., 2012). It was 
further demonstrated that metformin depleted a set 
of expression of cancer stem cell markers together 
with repression of miRNAS including miR-200c. 
Prolactinoma cancer 
Oncogenesis 
miR-200c was shown to be upregulated in a rat 
prolactinoma cell line, MMQ. A marine drug SZ-
685C induces apoptosis of these cells via 
downregulation of miR-200c. Moreover, 
overexpression of miR-200c was found to be 
attenuating the apoptotic effect of SZ-685C (Chen 
et al., 2013a). 
MIR200C (microRNA 200c) Mutlu M, et al. 
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Prostate cancer 
Prognosis 
Plasma levels of miR-200c has been identified as a 
potential biomarker to differentiate localized 
prostate cancer from metastatic castration resistant 
prostate cancer (Watahiki et al., 2013). 
Oncogenesis 
miRNA sequencing demostrated that miR-200c was 
upregulated in primary prostate carcinoma tissue 
(Szczyrba et al., 2011). In contrast, prostate cancer 
cells with EMT phenotype were found to have 
stem-cell like properties and express low levels of 
miR-200 family members (Kong et al., 2010). In 
approximately 50% of prostate cancer patients, 
chromosomal translocations that juxtapose the 
androgen-sensitive transmembrane protease, serine 
2 (TMPRSS2) gene promoter to the oncogenic 
ETS-family transcription factor ERG result in 
excessive ERG overexpression which in turn 
directly represses miR-200c and promotes EMT by 
upregulating ZEB1 (Kim et al., 2013). 
Overexpression of miR-200c reversed EMT and 
stem-cell like properties, in part due to targeting of 
Notch-1. miR-200c was also shown to target the 
Notch ligand Jagged1, resulting in decreased 
proliferation of metastatic prostate cancer cells 
(Vallejo et al., 2011). 
Renal cancer 
Disease 
Clear cell carcinoma (CCC); chromophobe renal 
cell carcinoma (ChCC). 
Prognosis 
Diagnosis. miR-200c has been found to be 
specifically expressed in ChCC and has been 
suggested as one of the microRNAs that can be 
used to distinguish between RCC subtypes 
(Fridman et al., 2010). In addition, miR-200c is one 
of the five miRNAs used as a biomarker subset 
allowing to characterize clear-cell renal cell 
carcinoma (ccRCC), papillary RCC (pRCC) types 1 
and 2 and normal tissue with high accuracy (Wach 
et al., 2013). 
Oncogenesis 
miR-200c was found to be significantly 
downregulated in CCC compared to normal kidney 
in a panel of 16 CCCs, 4 ChCCs and 6 normal 
kidneys both by microarray analysis and by qRT-
PCR (Nakada et al., 2008). Furthermore, miR-200c 
expression was inversely correlated with expression 
of its target gene ZEB1 in these specimens. The 
downregulation of miR-200c in CCC was also 
confirmed by a second study comparing a total of 
25 CCC and matched adjacent normal tissue (Liu et 
al., 2010). miR-200c has also been shown to be one 
of the most downregulated miRNAs in a 
comparative study with 70 matched pairs of clear 
cell renal cell carcinoma and normal kidney tissues 
(White et al., 2011).  
miR-200c negatively affects metastasis of RCC 
cells by upregulating E-cadherin upon ZEB1 in 
addition to its effective role on AKT protein. 
Hence, AKT-miR-200c-E-cadherin pathway may 
have importance in EMT within RCC. In a series of 
functional studies of mir-200c, it has been shown 
that induction of miR-200c expression by 
Ochratoxin A (OTA) in porcine renal proximal 
tubular cells attenuates Nrf2 and HO-1 expression 
and elevates ROS and profibrotic TGF-β expression 
(Stachurska et al., 2013). Furthermore, it has been 
demonstrated that the renal cortical content of miR-
200c was increased with aging. Increased miR-200c 
contents were associated with reduced expression 
of its target, ZEB2 (Sataranatarajan et al., 2012). 
Finally, multidrug resistance linked proteins 
appears to be prominently influenced by a set of 
five miRNAs including mir-200c used to 
discriminate renal tumor from normal tissue (Wach 
et al., 2013). 
Thyroid carcinoma 
Prognosis 
Diagnosis. Deregulated miR-200c, along with other 
miRNAs, has been reported as a marker for 
metastatic medullary thyroid carcinoma (Santarpia 
et al., 2013). 
Oncogenesis 
The expression of miR-200 family members, 
including miR-200c, was found to be 
downregulated in undifferentiated, aggressive 
anaplastic thyroid carcinoma compared to both 
normal tissue and well-differentiated papillary and 
follicular thyroid carcinomas (Braun et al., 2010). 
Overexpression of the miR-200 family induced 
mesenchymal-to-epithelial transition and reduced 
invasion of ATC cells. Overexpression of mir-200c 
in metastatic medullary thyroid carcinoma 
improves E-cadherin levels by directly targeting 
ZEB1 and ZEB2 or by enhanced expression of 
TGF-β (Santarpia et al., 2013). 
Wilms tumor 
Oncogenesis 
miRNA expression was analyzed in tissue samples 
including alveolar rhabdomyosarcoma (RMA) and 
malignant rhabdoid tumor (MRT) as well as in the 
rhabdomyosarcoma (RMS) cell lines (Rh30 and 
RD). It has been shown that miR-200c expression 
inhibits migration, and miR-200c was shown be 
expressed at a lower level in RMA than in MRT 
(Armeanu-Ebinger et al., 2012). 
Microbiota 
Cytogenetics 
The intestinal levels of miR-200c, together with 5 
other miRNAs, varied upon Listeria infection and 
MIR200C (microRNA 200c) Mutlu M, et al. 
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for 5 of these miRNAs including miR-200c, this 
alteration was found to be dependent on the 
presence of intestinal microbiota of mice 
(Archambaud et al., 2013). 
Obesity 
Cytogenetics 
microRNA expression analysis showed mouse 
miR-200c (mmu-miR-200c) downregulation in the 
presence of high fat diet in C57BLJ6 mice 
(Chartoumpekis et al., 2012). Leptin deficient ob/ob 
mice manifest up-regulated miR-200a, miR-200b 
and miR-429 levels and leptin treatment decreases 
the amount of these miRNAs. Besides, through 
overexpression and downregulation studies it was 
shown that miR-200a might be a target for obesity 
since its inverse expression relationship with leptin 
and insulin signaling (Crépin et al., 2014). 
Stem cells, differentiation and 
reprogramming 
Cytogenetics 
Direct transfection of three mature miRNAs (mir-
200c, -302s and -369s) with increased expression 
levels in embryonic stem cells and induced 
pluripotent stem cells can reprogram mouse and 
human cells to pluripotency. Transfection of 
miRNAs reduced the risk of mutations and 
tumorigenesis compared to induced pluripotent 
stem cells (IPSCs) by introduction of four 
transcription factors Oct3/4, Sox2, c-Myc and Klf4 
(Miyoshi et al., 2011; Miyazaki et al., 2012). miR-
200 family also regulates two of the Yamanaka 
factors Oct4/Sox2 in a specific manner and induces 
somatic cell reprogramming with the involvement 
of the miR-200/ZEB2 pathway (Wang et al., 2013). 
miR-200c, along with miR-150, has been reported 
to play an important role in human embryonic stem 
cell differentiation towards endothelial lineage and 
chick embryonic blood vessel formation by 
targeting ZEB1 (Luo et al., 2013). 
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